Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$4.80|
|52 Week High||AU$4.00|
|52 Week Low||AU$5.55|
|1 Month Change||1.48%|
|3 Month Change||-10.95%|
|1 Year Change||17.94%|
|3 Year Change||81.82%|
|5 Year Change||198.14%|
|Change since IPO||162.30%|
Recent News & Updates
Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued
How far off is Integral Diagnostics Limited ( ASX:IDX ) from its intrinsic value? Using the most recent financial data...
Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?
Today we'll take a closer look at Integral Diagnostics Limited ( ASX:IDX ) from a dividend investor's perspective...
|IDX||AU Healthcare||AU Market|
Return vs Industry: IDX exceeded the Australian Healthcare industry which returned 13.1% over the past year.
Return vs Market: IDX underperformed the Australian Market which returned 21.4% over the past year.
Stable Share Price: IDX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: IDX's weekly volatility (6%) has been stable over the past year.
About the Company
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. The company provides its services through 67 radiology clinics. Integral Diagnostics Limited was incorporated in 2008 and is headquartered in Melbourne, Australia.
Integral Diagnostics Fundamentals Summary
|IDX fundamental statistics|
Is IDX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IDX income statement (TTM)|
|Cost of Revenue||AU$221.45m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.16|
|Net Profit Margin||8.92%|
How did IDX perform over the long term?See historical performance and comparison
2.6%Current Dividend Yield
Is Integral Diagnostics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IDX (A$4.8) is trading below our estimate of fair value (A$8.07)
Significantly Below Fair Value: IDX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IDX is poor value based on its PE Ratio (30.7x) compared to the Australian Healthcare industry average (24.7x).
PE vs Market: IDX is poor value based on its PE Ratio (30.7x) compared to the Australian market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: IDX is poor value based on its PEG Ratio (2.1x)
Price to Book Ratio
PB vs Industry: IDX is overvalued based on its PB Ratio (3.8x) compared to the AU Healthcare industry average (2.2x).
How is Integral Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IDX's forecast earnings growth (14.7% per year) is above the savings rate (1.9%).
Earnings vs Market: IDX's earnings (14.7% per year) are forecast to grow faster than the Australian market (11.5% per year).
High Growth Earnings: IDX's earnings are forecast to grow, but not significantly.
Revenue vs Market: IDX's revenue (8.3% per year) is forecast to grow faster than the Australian market (5.3% per year).
High Growth Revenue: IDX's revenue (8.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IDX's Return on Equity is forecast to be low in 3 years time (15.8%).
How has Integral Diagnostics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IDX has high quality earnings.
Growing Profit Margin: IDX's current net profit margins (8.9%) are higher than last year (8.4%).
Past Earnings Growth Analysis
Earnings Trend: IDX's earnings have grown by 18.4% per year over the past 5 years.
Accelerating Growth: IDX's earnings growth over the past year (35.8%) exceeds its 5-year average (18.4% per year).
Earnings vs Industry: IDX earnings growth over the past year (35.8%) underperformed the Healthcare industry 61.3%.
Return on Equity
High ROE: IDX's Return on Equity (12.3%) is considered low.
How is Integral Diagnostics's financial position?
Financial Position Analysis
Short Term Liabilities: IDX's short term assets (A$82.3M) exceed its short term liabilities (A$77.9M).
Long Term Liabilities: IDX's short term assets (A$82.3M) do not cover its long term liabilities (A$322.3M).
Debt to Equity History and Analysis
Debt Level: IDX's debt to equity ratio (73.8%) is considered high.
Reducing Debt: IDX's debt to equity ratio has increased from 48.6% to 73.8% over the past 5 years.
Debt Coverage: IDX's debt is well covered by operating cash flow (37%).
Interest Coverage: IDX's interest payments on its debt are well covered by EBIT (5.7x coverage).
What is Integral Diagnostics's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: IDX's dividend (2.6%) is higher than the bottom 25% of dividend payers in the Australian market (2.27%).
High Dividend: IDX's dividend (2.6%) is low compared to the top 25% of dividend payers in the Australian market (5.31%).
Stability and Growth of Payments
Stable Dividend: IDX has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: IDX's dividend payments have increased, but the company has only paid a dividend for 5 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (79.1%), IDX's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: IDX's dividends in 3 years are forecast to be covered by earnings (61.8% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ian Kadish (58 yo)
Dr. Ian Kadish, MBBCh, MBA, has been the Chief Executive Officer, Managing Director and Director at Integral Diagnostics Limited since May 22, 2017. Dr. Kadish serves as Independent Non-Executive Director...
CEO Compensation Analysis
Compensation vs Market: Ian's total compensation ($USD1.16M) is about average for companies of similar size in the Australian market ($USD973.44K).
Compensation vs Earnings: Ian's compensation has increased by more than 20% in the past year.
Experienced Management: IDX's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: IDX's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Integral Diagnostics Limited's employee growth, exchange listings and data sources
- Name: Integral Diagnostics Limited
- Ticker: IDX
- Exchange: ASX
- Founded: 2008
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: AU$946.793m
- Shares outstanding: 200.17m
- Website: https://www.integraldiagnostics.com.au
Number of Employees
- Integral Diagnostics Limited
- 45 William Street
- Suite 9.02
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/22 07:05|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.